(Q34602552)

3 August 2017

1 reference

title

Prostate-specific antigen vaccines for prostate cancer (English)

1 reference

3 August 2017

1 reference

Heidi Hörig

1

1 reference

3 August 2017

Christopher S D Lee

series ordinal

2

1 reference

3 August 2017

Howard L Kaufman

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Expert Opinion on Biological Therapy

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

4

1 reference

3 August 2017

395-408

1 reference

Advances in prostate cancer

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Different responses of lymphoid cells from tumor-bearing as compared to tumor-immunized mice when sensitized to tumor specific antigens in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Cross-presentation, dendritic cells, tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Antigen-pulsed CD8alpha+ dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

The immunological synapse: a molecular machine controlling T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Natural killer cells in antiviral defense: function and regulation by innate cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

CD4 T cells and their role in antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Execution and suicide: cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Fas and FasL in the homeostatic regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Antigen processing and presentation by the class I major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Roles of heat-shock proteins in antigen presentation and cross-presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

A retrospective and prospective overview of prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Recombinant viruses as vaccines and immunological tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Poxvirus-based vectors as vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Follow-up evaluation of a phase II prostate cancer vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Three predominant proteins secreted by the human prostate gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Route of immunization and the therapeutic impact of recombinant anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.395

21 January 2018

Identifiers

DOI

10.1517/14712598.2.4.395

1 reference

3 August 2017

1 reference